Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177177 · ClinicalTrials.gov registry record · NA
L-carnosine for Schizophrenia
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
NCT00177177 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 84 participants.
The verdict
NCT00177177, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
Study Summary
The investigators' hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance cognitive abilities (specifically: measures of attention, executive function, working memory, visuospatial ability and language) in persons with schizophrenia or schizoaffective disorder. Secondarily, they hypothesize that there will be secondary improvements in positive, negative and mood symptoms with L-carnosine treatment. The investigators aim to test these hypotheses by conducting a randomized, placebo controlled, add-on treatment trial of L-carnosine (added to existing antipsychotic treatment) up to 84 recruited subjects with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) schizophrenia/schizoaffective disorder for a period of 16 weeks. Measures of cognition and psychopathology will be utilized for evaluating primary and secondary outcomes, along with safety assessments.
Interventions
- DRUG L-carnosine (dietary supplement)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177177
The ClinicalTrials.gov registry entry for NCT00177177 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-carnosine (dietary supplement) is the first listed.
NCT00177177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177177 about?
NCT00177177 is a clinical study titled "L-carnosine for Schizophrenia". The investigators' hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance cognitive abilities (specifically: measures of attention, executive function, working memory, visuospatial ability and language) in persons with schizophrenia or schizoaffective disorder. Seconda...
What is the current status of trial NCT00177177?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2004-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00177177?
The interventions under investigation include: L-carnosine (dietary supplement) (DRUG).
Who is sponsoring clinical trial NCT00177177?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.